8-K - Vistagen Therapeutics, Inc. (0001411685) (Filer)
Published . Updated .
Key takeaways
- 8-K - Vistagen Therapeutics filed an 8-K with the SEC on Oct 30 (a notice of a material company event).
- Exposed: VTGN
- Market reaction: VTGN +0.5% by the next session
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
Get these market calls by email
The week's biggest market-moving stories, Congress trades and Trump posts, with the tickers they touch. Free, one email a week.
Free. We only use your email to send the digest, never sell or share it, and every email has a one-click unsubscribe link. See our privacy policy.
8-K - Vistagen Therapeutics filed an 8-K with the SEC on Oct 30 (a notice of a material company event).
Directly affected
- VTGN Vistagen Therapeutics-29.7% 17d
Named in this report.
Indirectly affected
- XLV Health Care Select Sector SPDR
Health Care Select Sector SPDR holds the health sector that Vistagen Therapeutics belongs to, so it often moves with news about it.
- LLY Eli Lilly and+20.6% 30d
Eli Lilly and is a peer of Vistagen Therapeutics in pharmaceutical preparations; rivals often move on the same news.
- JNJ Johnson & Johnson+0.5% 30d
Johnson & Johnson is a peer of Vistagen Therapeutics in pharmaceutical preparations; rivals often move on the same news.
- ABBV AbbVie+8.9% 30d
AbbVie is a peer of Vistagen Therapeutics in pharmaceutical preparations; rivals often move on the same news.
- MRK Merck+4.6% 17d
Merck is a peer of Vistagen Therapeutics in pharmaceutical preparations; rivals often move on the same news.
- ABT Abbott Laboratories+7.7% 30d
Abbott Laboratories is a peer of Vistagen Therapeutics in pharmaceutical preparations; rivals often move on the same news.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| VTGN | +3.27% | -0.60% | base | -0.83% | +0.54% | after close | after close |
| XLV | -3.03% | -2.77% | base | -0.14% | -0.48% | after close | after close |
| LLY | -9.71% | -8.92% | base | -0.37% | -0.54% | after close | after close |
| JNJ | -2.53% | -0.72% | base | -0.98% | -2.59% | after close | after close |
| ABBV | -2.71% | -2.90% | base | -2.03% | -3.03% | after close | after close |
| MRK | -5.94% | -5.65% | base | -0.74% | -3.26% | after close | after close |
| ABT | -1.26% | -3.36% | base | +3.81% | +2.97% | after close | after close |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
Filed: 2026-10-30 AccNo: 0001628280-26-068627 Size: 140 KB Item 2.05: Cost Associated with Exit or Disposal Activities Item 8.01: Other Events
Source: sec-edgar
Vistagen Therapeutics (VTGN) since this story, compared with the market
| Company | When | Move | Status |
|---|---|---|---|
| ABBV | that day | -2.03% | final price |
| ABBV | the next day | -3.03% | final price |
| ABBV | three days earlier | -2.90% | final price |
| ABBV | five days earlier | -2.71% | final price |
| ABT | that day | +3.81% | final price |
| ABT | the next day | +2.97% | final price |
| ABT | three days earlier | -3.36% | final price |
| ABT | five days earlier | -1.26% | final price |
| JNJ | that day | -0.98% | final price |
| JNJ | the next day | -2.59% | final price |
| JNJ | three days earlier | -0.72% | final price |
| JNJ | five days earlier | -2.53% | final price |
| LLY | that day | -0.37% | final price |
| LLY | the next day | -0.54% | final price |
| LLY | three days earlier | -8.92% | final price |
| LLY | five days earlier | -9.71% | final price |
| MRK | that day | -0.74% | final price |
| MRK | the next day | -3.26% | final price |
| MRK | three days earlier | -5.65% | final price |
| MRK | five days earlier | -5.94% | final price |
| Vistagen Therapeutics (VTGN) | that day | -0.83% | final price |
| Vistagen Therapeutics (VTGN) | the next day | +0.54% | final price |
| Vistagen Therapeutics (VTGN) | three days earlier | -0.60% | final price |
| Vistagen Therapeutics (VTGN) | five days earlier | +3.27% | final price |
| XLV | that day | -0.14% | final price |
| XLV | the next day | -0.48% | final price |
| XLV | three days earlier | -2.77% | final price |
| XLV | five days earlier | -3.03% | final price |
Congressional trades in the stocks in this story
- Rep. Rohit Khanna bought Eli Lilly (LLY) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 56 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Thomas H. Kean Jr sold Johnson & Johnson (JNJ), worth $1,001 - $15,000 on 30 Sep 2026. That is 30 days before publication. Filed 30 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Johnson & Johnson (JNJ) (held by a spouse), worth $1,001 - $15,000 on 25 Sep 2026. That is 35 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Lloyd Doggett bought Johnson & Johnson (JNJ), worth $1,001 - $15,000 on 8 Sep 2026. That is 52 days before publication. Filed 5 Oct 2026. View the filing.
- Rep. Pete Sessions sold AbbVie (ABBV), worth $15,001 - $50,000 on 14 Sep 2026. That is 46 days before publication. Filed 18 Sep 2026. View the filing.
- Rep. Rohit Khanna sold AbbVie (ABBV) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 56 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar sold Merck (MRK), worth $1,001 - $15,000 on 24 Sep 2026. That is 36 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar bought Merck (MRK), worth $15,001 - $50,000 on 19 Aug 2026. That is 72 days before publication. Filed 9 Sep 2026. View the filing.
- Rep. Pete Sessions sold Abbott Laboratories (ABT) (held by a spouse), worth $50,001 - $100,000 on 2 Oct 2026. That is 28 days before publication. Filed 27 Oct 2026. View the filing.
- Rep. Gilbert Cisneros bought Abbott Laboratories (ABT), worth $1,001 - $15,000 on 18 Sep 2026. That is 42 days before publication. Filed 12 Oct 2026. View the filing.
- Rep. Thomas H. Kean Jr sold Abbott Laboratories (ABT), worth $1,001 - $15,000 on 17 Sep 2026. That is 43 days before publication. Filed 30 Oct 2026. View the filing.
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
Who gains and who loses around Vistagen Therapeutics (VTGN)
Companies carried with this story
- VTGN Vistagen Therapeutics
In “8-K - Vistagen Therapeutics, Inc. (0001411685) (Filer),” Vistagen Therapeutics (VTGN) is linked, with no stored direction, high confidence. Reason on file: SEC 8-K filing -> direct issuer disclosure -> VTGN
How “8-K - Vistagen Therapeutics, Inc. (0001411685) (Filer)” reaches Vistagen Therapeutics (VTGN)
Vistagen Therapeutics (VTGN) is the company in “8-K - Vistagen Therapeutics, Inc. (0001411685) (Filer),” the 30 Oct 2026 this story story.
The link for Vistagen Therapeutics (VTGN) is this: SEC 8-K filing -> direct issuer disclosure -> VTGN
The price range for Vistagen Therapeutics (VTGN), and the dates in the story
VTGN traded between 0.17 and 0.24 across 17 sessions. The latest close on file is 0.17.
What the saved facts support for Vistagen Therapeutics (VTGN)
14 out of 100
“8-K - Vistagen Therapeutics, Inc. (0001411685) (Filer)” scores 14 out of 100. The score uses 1 sources, and 1 linked companies.